Lúcio Gama

University of North Carolina at Chapel Hill — United States

Immunology and Microbiology · Life Sciences

43h-index5.4kcitations156works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(101), HIV/AIDS drug development and treatment(32), HIV/AIDS Research and Interventions(31), Immune Cell Function and Interaction(25), Monoclonal and Polyclonal Antibodies Research(18)

Publications156 total

Correlates of HIV-1 control after combination immunotherapy
Nature·2025· 6 citedOpen Access
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat
UNC Libraries·2025Open Access
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
Clinical Infectious Diseases·2025· 2 cited
Prebiotic Treatment During Pregnancy Prevents Social Deficits Associated to Autism Spectrum Disorder-Like Behavior Induced by Maternal Immune Activation
Preprints.org·2025Open Access
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data
Journal of the International AIDS Society·2025· 2 citedOpen Access
Broadly neutralizing antibodies, nonneutralizing antibodies and broadly effector antibodies to prevent HIV transmission?
AIDS·2025· 2 citedOpen Access
Combination immunotherapy induces post-intervention control of HIV
2025· 8 citedOpen Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
UNC Libraries·2025Open Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
BMC Immunology·2025· 3 citedOpen Access
Uso de análogos de GLP-1 e Doença Renal Crônica
Revista Eletrônica Acervo Saúde·2025Open Access
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
UNC Libraries·2025Open Access
Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07–523LS in Newborn Infants Exposed to HIV-1
Journal of the Pediatric Infectious Diseases Society·2025· 5 citedOpen Access
Safety, Pharmacokinetics, and Neutralization Activity of PGDM1400LS, VRC07-523-LS, and PGT121.414.LS Infused Intravenously or Subcutaneously: A Phase 1 Randomized Trial (HVTN 140/HPTN 101 Part B)
SSRN Electronic Journal·2025Open Access
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
The Lancet HIV·2024· 7 citedOpen Access
HIV drug resistance, viral suppression, and survival in children living with HIV in Brazil
HIV Medicine·2024· 2 cited
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial
Nature Medicine·2024· 40 citedOpen Access
Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIVAD8-EO infection
Nature Communications·2024· 10 citedOpen Access
Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial
BMC Infectious Diseases·2024· 2 citedOpen Access
Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial Acronym: PedMAb1
2024Open Access
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
UNC Libraries·2024Open Access
page 1 of 8Next →

Frequent Co-authors

Janice E. Clements(28), Joseph L. Mankowski(16), Suzanne E. Queen(12), Erin N. Shirk(12), M. Christine Zink(11), Celina Monteiro Abreu(10), Ming Li(10), Brandon Bullock(8), Gerda E. Breitwieser(7), Kelly A. Metcalf Pate(7), Richard A. Koup(7), Rebecca T. Veenhuis(5), John R. Mascola(5), Robert J. Adams(5), Kenneth W. Witwer(4), Claudia R. Avalos(4), Sarah L. Price(4), David R. Graham(4), Patrick M. Tarwater(4), Sarah E. Beck(4)